Few studies examine how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) tests assist or hinder efforts to prevent illness, hospitalisations, or people dying. Due to weak evidence, we’re ...
XFG, a recombinant of LF.7 and LP.8.1.2, is growing globally and predominates in Europe, although its impact on hospitals remains limited according to the ECDC and WHO.
Neutralizing antibodies that merely block receptor binding are losing ground against heavily mutated SARS-CoV-2 Omicron sub-variants. A new approach now exploits a llama-derived nanobody—VHH21—that ...
An international team of scientists has generated a new ring-shaped protein nanomaterial capable of strongly binding to and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback